Publications by authors named "R L Eefsen"
Background: Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approaches offers a potential strategy to address these challenges. Tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virus therapy represent promising treatment modalities that may synergize with each other.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the efficacy and safety of nadunolimab, an antibody targeting the IL-1 receptor, when combined with the chemotherapy regimen gemcitabine/nab-paclitaxel (GN) in patients with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
- A total of 76 patients were enrolled, revealing that neutropenia was the most common severe adverse effect, and the median overall survival (OS) was 13.2 months, with a 1-year survival rate of 58%.
- Results suggest that nadunolimab is both effective and safe, particularly showing better outcomes in patients with high baseline tumor IL1RAP expression, along with a correlation between reduced
Article Synopsis
- The study investigates DNA damage repair (DDR) pathways and their impact on treating metastatic castration-resistant prostate cancer (mCRPC), especially focusing on poly ADP ribose polymerase (PARP) inhibitors (PARPi).
- Out of 114 patients, specific gene alterations were linked to varying responses to PARPi, showing that those without the TMPRSS2:ERG gene fusion and with certain homozygous alterations benefitted more from the treatment.
- The findings suggest that the presence of the TMPRSS2:ERG fusion may indicate resistance to PARPi, indicating its potential as a biomarker for treatment outcomes.
Article Synopsis
- - This study evaluated the safety and effectiveness of Debio 1347, a new oral drug targeting FGFR fusions in patients with advanced solid tumors, focusing on its ability to produce objective responses and other outcomes in different cancer types.
- - A total of 63 patients participated, with only a 5% objective response rate, leading to the trial's early termination due to lower-than-expected effectiveness, despite manageable side effects like hyperphosphatemia and stomatitis.
- - The findings suggest that while the drug has some tolerance, its lack of significant efficacy means it should not undergo further testing for FGFR fusion tumors; the study also provided insight into the characteristics of FGFR fusions in solid tumors.
Radiotherapy is one of the most common cancer treatments, yet, some patients require high doses to respond. Therefore, the development of new strategies leans toward personalizing therapy to avoid unnecessary burden on cancer patients. This approach prevents the administration of ineffective treatments or uses combination strategies to increase the sensitivity of cancer cells.
View Article and Find Full Text PDF